Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.
ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.
Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey ...
ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results